Three years after regulatory approval, tirzepatide's real-world performance data is now substantial — and the Phase IV evidence continues to support what Phase III trials showed: a dual GIP/GLP-1 receptor agonist that produces weight loss outcomes significantly exceeding those of GLP-1 monotherapy. A new publication in the New England Journal of Medicine synthesizes real-world registry data from over 18,000 patients maintained on the 15mg weekly dose, providing the most comprehensive long-term picture to date.
Phase IV finding: In real-world registry data, patients maintaining tirzepatide 15mg weekly sustained over 20% total body weight loss at 36 months, with significant cardiovascular risk marker improvements versus GLP-1 monotherapy comparators.
Background: What Makes Tirzepatide Different
Tirzepatide is structurally distinct from semaglutide and other GLP-1 receptor agonists in that it acts on two incretin receptors simultaneously — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). The GIP receptor component was initially controversial; some researchers questioned whether GIP agonism would actually add benefit or even attenuate GLP-1 effects. The clinical data has consistently shown that the combination produces superior weight loss outcomes compared to GLP-1 agonism alone, though the precise mechanistic reason for this synergy remains under active investigation.
36-Month Outcomes in Real-World Data
Cardiovascular Outcomes
The Phase IV registry analysis included a pre-specified cardiovascular outcomes comparison versus a propensity-matched cohort of GLP-1 monotherapy patients (predominantly semaglutide). Key cardiovascular findings at 36 months included:
- Systolic blood pressure: −8 mmHg mean reduction versus baseline; significantly greater than GLP-1 comparator group (−4.5 mmHg, p<0.001).
- LDL cholesterol: Mean −12% reduction, with a trend toward greater improvement versus GLP-1 monotherapy that did not reach statistical significance.
- MACE events: A 19% relative risk reduction in major adverse cardiovascular events versus GLP-1 comparator, though the study was not powered as a cardiovascular outcomes trial and this finding should be interpreted cautiously.
- HbA1c: In the T2DM subgroup, mean HbA1c reduction of 1.8% at 36 months, with 71% of that subgroup achieving HbA1c below 7.0%.
Weight Loss Durability
One of the most clinically significant aspects of this data is the durability of weight loss. Earlier GLP-1 data showed meaningful weight regain upon discontinuation — a finding that generated controversy about whether treatment was creating dependency. The tirzepatide 36-month data shows that among patients who maintained therapy, weight loss did not plateau in the typical fashion observed with earlier agents; a subset of patients continued to lose small amounts of weight between months 24 and 36.
The study does not address discontinuation outcomes — a significant gap, as discontinuation rates and post-cessation weight trajectory are highly relevant to evaluating real-world benefit.
Adverse Events at 3 Years
The most commonly reported adverse events remained gastrointestinal — nausea, constipation, and diarrhea — consistent with Phase III data. Rates of these events decreased substantially after the first 6 months as patients achieved stable dosing. Serious adverse events were reported in 8.3% of the cohort over 36 months, consistent with background rates expected in this metabolically complex population. No new safety signals emerged at the 36-month mark beyond what was established in clinical trials.
What This Means for the Field
The tirzepatide 36-month data reinforces that dual incretin agonism represents a meaningful therapeutic advance over GLP-1 monotherapy for weight management and metabolic disease. For the broader peptide and metabolic research community, the data also validates GIP receptor engagement as a useful therapeutic target — opening research directions for more selective or structurally novel compounds in this receptor class.